SynthesisBioMed research international2015
Ocular Manifestations and Therapeutic Options in Patients with Familial Amyloid Polyneuropathy: A Systematic Review.
Synthesis in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 47 citations in OpenAlex.
- Intraocular amyloidosis presenting with secondary glaucoma: a clinical-pathologic report and literature review.American journal of ophthalmology case reports · 2026Article
- Cyclosporine eye drops in lattice corneal dystrophy type 1: case report.Annals of medicine and surgery (2012) · 2025Article
- Hereditary vitreoretinal amyloidosis with transthyretin Gly83Arg variant, a long-term study.Eye (London, England) · 2025Article
- Modified Technique of Ex-PRESSClinical ophthalmology (Auckland, N.Z.) · 2023Article
- Clinical features of retinal amyloid angiopathy with transthyretin Gly83Arg variant.International journal of ophthalmology · 2023Article
- Hereditary transthyretin amyloidosis overview.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Review
- Ahmed valve for secondary glaucoma in patients with hereditary transthyretin amyloidosis.Eye (London, England) · 2022Article
- Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression.Orphanet journal of rare diseases · 2021Article
- Ocular Involvement in Hereditary Amyloidosis.Genes · 2021Review
- Observational
- Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.Journal of neurology · 2021Review
- siRNA Therapeutics in Ocular Diseases.Methods in molecular biology (Clifton, N.J.) · 2021Review
- Interplay between Oxidative Stress, Inflammation, and Amyloidosis in the Anterior Segment of the Eye; Its Pathological Implications.Oxidative medicine and cellular longevity · 2020Review
- Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care.Therapeutics and clinical risk management · 2020Review
- Reliability of the Evidence Addressing Treatment of Corneal Diseases: A Summary of Systematic Reviews.JAMA ophthalmology · 2019Article
- Visualization of multiple organ amyloid involvement in systemic amyloidosis usingEuropean journal of nuclear medicine and molecular imaging · 2018Article
- Apolipoprotein AI-Derived Vitreous Amyloidosis: An Elusive Diagnosis.Case reports in ophthalmologyArticle
- Ophthalmological manifestations of hereditary transthyretin amyloidosis.Arquivos brasileiros de oftalmologiaReview
- Transscleral Cyclophotocoagulation in Familial Amyloidotic Polyneuropathy Secondary Glaucoma after Ahmed Valve Implantation: A Case Series Study.Journal of current glaucoma practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis paper aims to review the morphological and functional characteristics of patients affected by familial amyloid polyneuropathy (FAP), with greater focus on type I and its progression after liver transplantation. We also analyse therapeutic options for the ophthalmic manifestations.
methodsThe literature from 2002 through 2015 was reviewed, with a total of 45 articles studied, using the key terms related to amyloidosis and its therapeutic approaches. Information was collated, evaluated, critically assessed, and then summarised in its present form. PATHOPHYSIOLOGY AND TREATMENT: FAP results from mutation of the transthyretin gene, with Val30Met being the most frequent substitution. The symptoms are those typical of a sensorimotor autonomic neuropathy and can be halted with liver transplantation. Nowadays there are new medical therapies that delay the progression of the systemic neuropathy. However, there are still no options to avoid ocular disease.
conclusionThe main ocular manifestations in patients with FAP type I are amyloid deposition in the vitreous, dry eye, and secondary glaucoma. Despite liver transplantation, eye synthesis of amyloid persists and is associated with progressive ocular manifestations, which require continued ophthalmologic follow-up. New therapeutic strategies are therefore needed, particularly to target the ocular synthesis of the abnormal protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.